Position in UPB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,751,396
New position
Shares Held
253,092
first reported quarter
Ownership
0.462%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#37
of 148 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 98%
Shared 0%
None 2%
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. UPB ranks #47 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in UPB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,751,396 | 253,092 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||